Lantern
Lantern Pharma is a leading clinical-stage oncology company that uses artificial intelligence (AI), machine learning, and genomics to develop targeted cancer therapies. Lantern develops therapies using genomic data, computational biology modeling, and AI techniques via it’s proprietary RADR® platform to clarify the potential mechanism of action underlying drug-tumor response and to identify the patient groups most likely to respond to a therapy. In short, Lantern Pharma is leveraging AI and machine learning to speed drug discovery and drug development with the goal of changing the lives of thousand of cancer patients around the world. Although promising and intriguing, gaining visibility in the competitive and crowded oncology news environment posed challenges, especially for a company whose drugs, while in clinical trials, were not yet on market. Media skepticism regarding AI potential for effective drug discovery would also need to be addressed.
Our approach started with our outreach to top-tier health, oncology, technology and business outlets and podcasts. We focused on technological advance and RADR’s® ability to cut the drug development process timeline by years, bringing hope to patients in need of new options. With non-small cell lung cancer as a drug target, we focused on patient stories, particularly highlighting never smokers – i.e., those who have never smoked, yet still developed lung cancer – to underscore the importance of Lantern Pharma’s research. We crafted timely pitches surrounding trending media news, patient testimonials and expert commentary from Lantern Pharma’s roster of MDs and researchers and leveraged our proprietary Interviewed technology to consistently monitored for ways to interrupt the news cycle and insert the brand into trending stories.
In just 10 months, Interdependence secured 30 earned media placements resulting in more than 11 million targeted media impressions.
Audience
Effectively reached key audiences within oncology, technology, health, consumer and business spaces
Key Outlets
Secured coverage key outlets such as Washington Examiner, Labiotech, BioWorld, Targeted Oncology and Cancer Network, among others.
Secured Interviews
Secured interviews with Bloomberg, The Street, the Washington Examiner and multiple high-level medical trade outlets.
Created Content
Developed and drafted thought leader bylines for Pharmacy Times and PharmiWeb,as well as OP-EDs addressing the critical need for research and options meeting the specific needs of never smokers who have developed non-small cell lung cancer.
See increases of 300-400% in conversion rates powering far more media placements.
